Citius Oncology, Inc. (NASDAQ: CTOR) Stock Competitors & Peer Comparison
See CTOR's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Pharmaceuticals Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for CTOR and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| CTOR | $0.76 | -10.66% | 78.9M | -1.81 | -$0.47 | N/A |
| RPRX | $56.56 | -0.65% | 25.6B | 11.01 | $5.25 | +1.60% |
| CORT | $118.00 | -1.34% | 12.8B | 338.69 | $0.35 | N/A |
| WBA | $11.98 | +0.50% | 10.4B | -1.64 | -$7.29 | +4.17% |
| KNSA | $78.64 | -1.43% | 6B | 81.69 | $0.97 | N/A |
| LQDA | $26.80 | -2.12% | 2.5B | 20.20 | $1.37 | N/A |
| PBH | $49.05 | +1.70% | 2.3B | 11.09 | $4.42 | N/A |
| HROWL | $25.61 | +0.19% | 1.4B | N/A | N/A | N/A |
| HROWM | $26.03 | -0.08% | 1.3B | N/A | N/A | N/A |
| LTGO | $16.00 | -0.03% | 963.7M | -6.36 | -$2.52 | N/A |
Stock Comparison
Royalty Pharma plc (NASDAQ: RPRX)
CTOR vs RPRX Comparison October 2026
Citius Oncology, Inc. (NASDAQ: CTOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTOR stands at 78.9M. In comparison, RPRX has a market cap of 25.6B. Regarding current trading prices, CTOR is priced at $0.76 on the NASDAQ, while RPRX trades at $56.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTOR currently has a P/E ratio of -1.81, whereas RPRX's P/E ratio is 11.01. In terms of profitability, CTOR's ROE is -1.03%, compared to RPRX's ROE of +0.12%. Regarding short-term risk, CTOR is more volatile compared to RPRX. This indicates higher risk in terms of short-term price fluctuations for CTOR.Check RPRX's competition here
Corcept Therapeutics Incorporated (NASDAQ: CORT)
CTOR vs CORT Comparison October 2026
Citius Oncology, Inc. (NASDAQ: CTOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTOR stands at 78.9M. In comparison, CORT has a market cap of 12.8B. Regarding current trading prices, CTOR is priced at $0.76 on the NASDAQ, while CORT trades at $118.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTOR currently has a P/E ratio of -1.81, whereas CORT's P/E ratio is 338.69. In terms of profitability, CTOR's ROE is -1.03%, compared to CORT's ROE of +0.08%. Regarding short-term risk, CTOR is more volatile compared to CORT. This indicates higher risk in terms of short-term price fluctuations for CTOR.Check CORT's competition here
Walgreens Boots Alliance, Inc. (NASDAQ: WBA)
CTOR vs WBA Comparison October 2026
Citius Oncology, Inc. (NASDAQ: CTOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTOR stands at 78.9M. In comparison, WBA has a market cap of 10.4B. Regarding current trading prices, CTOR is priced at $0.76 on the NASDAQ, while WBA trades at $11.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTOR currently has a P/E ratio of -1.81, whereas WBA's P/E ratio is -1.64. In terms of profitability, CTOR's ROE is -1.03%, compared to WBA's ROE of -0.57%. Regarding short-term risk, CTOR is more volatile compared to WBA. This indicates higher risk in terms of short-term price fluctuations for CTOR.Check WBA's competition here
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA)
CTOR vs KNSA Comparison October 2026
Citius Oncology, Inc. (NASDAQ: CTOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTOR stands at 78.9M. In comparison, KNSA has a market cap of 6B. Regarding current trading prices, CTOR is priced at $0.76 on the NASDAQ, while KNSA trades at $78.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTOR currently has a P/E ratio of -1.81, whereas KNSA's P/E ratio is 81.69. In terms of profitability, CTOR's ROE is -1.03%, compared to KNSA's ROE of +0.14%. Regarding short-term risk, CTOR is more volatile compared to KNSA. This indicates higher risk in terms of short-term price fluctuations for CTOR.Check KNSA's competition here
Liquidia Corporation (NASDAQ: LQDA)
CTOR vs LQDA Comparison October 2026
Citius Oncology, Inc. (NASDAQ: CTOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTOR stands at 78.9M. In comparison, LQDA has a market cap of 2.5B. Regarding current trading prices, CTOR is priced at $0.76 on the NASDAQ, while LQDA trades at $26.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTOR currently has a P/E ratio of -1.81, whereas LQDA's P/E ratio is 20.20. In terms of profitability, CTOR's ROE is -1.03%, compared to LQDA's ROE of +1.50%. Regarding short-term risk, CTOR is more volatile compared to LQDA. This indicates higher risk in terms of short-term price fluctuations for CTOR.Check LQDA's competition here
Prestige Consumer Healthcare Inc. (NYSE: PBH)
CTOR vs PBH Comparison October 2026
Citius Oncology, Inc. (NASDAQ: CTOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTOR stands at 78.9M. In comparison, PBH has a market cap of 2.3B. Regarding current trading prices, CTOR is priced at $0.76 on the NASDAQ, while PBH trades at $49.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTOR currently has a P/E ratio of -1.81, whereas PBH's P/E ratio is 11.09. In terms of profitability, CTOR's ROE is -1.03%, compared to PBH's ROE of +0.09%. Regarding short-term risk, CTOR is more volatile compared to PBH. This indicates higher risk in terms of short-term price fluctuations for CTOR.Check PBH's competition here
Harrow Health, Inc. 8.625% Senior Notes due 2026 (NASDAQ: HROWL)
CTOR vs HROWL Comparison October 2026
Citius Oncology, Inc. (NASDAQ: CTOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTOR stands at 78.9M. In comparison, HROWL has a market cap of 1.4B. Regarding current trading prices, CTOR is priced at $0.76 on the NASDAQ, while HROWL trades at $25.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTOR currently has a P/E ratio of -1.81, whereas HROWL's P/E ratio is N/A. In terms of profitability, CTOR's ROE is -1.03%, compared to HROWL's ROE of -1.04%. Regarding short-term risk, CTOR is more volatile compared to HROWL. This indicates higher risk in terms of short-term price fluctuations for CTOR.Check HROWL's competition here
Harrow Health, Inc. 11.875% Senior Notes due 2027 (NASDAQ: HROWM)
CTOR vs HROWM Comparison October 2026
Citius Oncology, Inc. (NASDAQ: CTOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTOR stands at 78.9M. In comparison, HROWM has a market cap of 1.3B. Regarding current trading prices, CTOR is priced at $0.76 on the NASDAQ, while HROWM trades at $26.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTOR currently has a P/E ratio of -1.81, whereas HROWM's P/E ratio is N/A. In terms of profitability, CTOR's ROE is -1.03%, compared to HROWM's ROE of -1.04%. Regarding short-term risk, CTOR is more volatile compared to HROWM. This indicates higher risk in terms of short-term price fluctuations for CTOR.Check HROWM's competition here
Latigo Biotherapeutics Inc. (NASDAQ: LTGO)
CTOR vs LTGO Comparison October 2026
Citius Oncology, Inc. (NASDAQ: CTOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTOR stands at 78.9M. In comparison, LTGO has a market cap of 963.7M. Regarding current trading prices, CTOR is priced at $0.76 on the NASDAQ, while LTGO trades at $16.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTOR currently has a P/E ratio of -1.81, whereas LTGO's P/E ratio is -6.36. In terms of profitability, CTOR's ROE is -1.03%, compared to LTGO's ROE of N/A. Regarding short-term risk, CTOR is more volatile compared to LTGO. This indicates higher risk in terms of short-term price fluctuations for CTOR.Check LTGO's competition here
Helus Pharma Inc. (NASDAQ: HELP)
CTOR vs HELP Comparison October 2026
Citius Oncology, Inc. (NASDAQ: CTOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTOR stands at 78.9M. In comparison, HELP has a market cap of 683.7M. Regarding current trading prices, CTOR is priced at $0.76 on the NASDAQ, while HELP trades at $10.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTOR currently has a P/E ratio of -1.81, whereas HELP's P/E ratio is -2.65. In terms of profitability, CTOR's ROE is -1.03%, compared to HELP's ROE of -0.71%. Regarding short-term risk, CTOR is more volatile compared to HELP. This indicates higher risk in terms of short-term price fluctuations for CTOR.Check HELP's competition here
Sinovac Biotech Ltd. (NASDAQ: SVA)
CTOR vs SVA Comparison October 2026
Citius Oncology, Inc. (NASDAQ: CTOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTOR stands at 78.9M. In comparison, SVA has a market cap of 464.9M. Regarding current trading prices, CTOR is priced at $0.76 on the NASDAQ, while SVA trades at $6.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTOR currently has a P/E ratio of -1.81, whereas SVA's P/E ratio is -5.68. In terms of profitability, CTOR's ROE is -1.03%, compared to SVA's ROE of -0.01%. Regarding short-term risk, CTOR is more volatile compared to SVA. This indicates higher risk in terms of short-term price fluctuations for CTOR.Check SVA's competition here
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL)
CTOR vs CUVL Comparison October 2026
Citius Oncology, Inc. (NASDAQ: CTOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTOR stands at 78.9M. In comparison, CUVL has a market cap of 281.4M. Regarding current trading prices, CTOR is priced at $0.76 on the NASDAQ, while CUVL trades at $5.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTOR currently has a P/E ratio of -1.81, whereas CUVL's P/E ratio is 12.04. In terms of profitability, CTOR's ROE is -1.03%, compared to CUVL's ROE of N/A. Regarding short-term risk, CTOR is more volatile compared to CUVL. This indicates higher risk in terms of short-term price fluctuations for CTOR.Check CUVL's competition here
High Tide Inc. (NASDAQ: HITI)
CTOR vs HITI Comparison October 2026
Citius Oncology, Inc. (NASDAQ: CTOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTOR stands at 78.9M. In comparison, HITI has a market cap of 226.7M. Regarding current trading prices, CTOR is priced at $0.76 on the NASDAQ, while HITI trades at $2.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTOR currently has a P/E ratio of -1.81, whereas HITI's P/E ratio is -9.53. In terms of profitability, CTOR's ROE is -1.03%, compared to HITI's ROE of -0.36%. Regarding short-term risk, CTOR is more volatile compared to HITI. This indicates higher risk in terms of short-term price fluctuations for CTOR.Check HITI's competition here
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI)
CTOR vs CELG-RI Comparison October 2026
Citius Oncology, Inc. (NASDAQ: CTOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTOR stands at 78.9M. In comparison, CELG-RI has a market cap of 224.7M. Regarding current trading prices, CTOR is priced at $0.76 on the NASDAQ, while CELG-RI trades at $0.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTOR currently has a P/E ratio of -1.81, whereas CELG-RI's P/E ratio is N/A. In terms of profitability, CTOR's ROE is -1.03%, compared to CELG-RI's ROE of +0.47%. Regarding short-term risk, CTOR is more volatile compared to CELG-RI. This indicates higher risk in terms of short-term price fluctuations for CTOR.Check CELG-RI's competition here
Electra Therapeutics Inc. (NASDAQ: ETRA)
CTOR vs ETRA Comparison October 2026
Citius Oncology, Inc. (NASDAQ: CTOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTOR stands at 78.9M. In comparison, ETRA has a market cap of 197.7M. Regarding current trading prices, CTOR is priced at $0.76 on the NASDAQ, while ETRA trades at $9.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTOR currently has a P/E ratio of -1.81, whereas ETRA's P/E ratio is -3.52. In terms of profitability, CTOR's ROE is -1.03%, compared to ETRA's ROE of N/A. Regarding short-term risk, CTOR is more volatile compared to ETRA. This indicates higher risk in terms of short-term price fluctuations for CTOR.Check ETRA's competition here
TRex Bio Inc. (NASDAQ: TRXB)
CTOR vs TRXB Comparison October 2026
Citius Oncology, Inc. (NASDAQ: CTOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTOR stands at 78.9M. In comparison, TRXB has a market cap of 116.9M. Regarding current trading prices, CTOR is priced at $0.76 on the NASDAQ, while TRXB trades at $13.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTOR currently has a P/E ratio of -1.81, whereas TRXB's P/E ratio is N/A. In terms of profitability, CTOR's ROE is -1.03%, compared to TRXB's ROE of N/A. Regarding short-term risk, CTOR is more volatile compared to TRXB. This indicates higher risk in terms of short-term price fluctuations for CTOR.Check TRXB's competition here
Atlantic International Corp. (NASDAQ: ATLN)
CTOR vs ATLN Comparison October 2026
Citius Oncology, Inc. (NASDAQ: CTOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTOR stands at 78.9M. In comparison, ATLN has a market cap of 68.6M. Regarding current trading prices, CTOR is priced at $0.76 on the NASDAQ, while ATLN trades at $0.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTOR currently has a P/E ratio of -1.81, whereas ATLN's P/E ratio is -0.68. In terms of profitability, CTOR's ROE is -1.03%, compared to ATLN's ROE of -83.20%. Regarding short-term risk, CTOR is less volatile compared to ATLN. This indicates lower risk in terms of short-term price fluctuations for CTOR.Check ATLN's competition here
Retension Pharmaceuticals Inc. (NASDAQ: RTSN)
CTOR vs RTSN Comparison October 2026
Citius Oncology, Inc. (NASDAQ: CTOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTOR stands at 78.9M. In comparison, RTSN has a market cap of 43.7M. Regarding current trading prices, CTOR is priced at $0.76 on the NASDAQ, while RTSN trades at $12.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTOR currently has a P/E ratio of -1.81, whereas RTSN's P/E ratio is N/A. In terms of profitability, CTOR's ROE is -1.03%, compared to RTSN's ROE of N/A. Regarding short-term risk, CTOR is more volatile compared to RTSN. This indicates higher risk in terms of short-term price fluctuations for CTOR.Check RTSN's competition here
Rite Aid Corporation (NYSE: RAD)
CTOR vs RAD Comparison October 2026
Citius Oncology, Inc. (NASDAQ: CTOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTOR stands at 78.9M. In comparison, RAD has a market cap of 36.8M. Regarding current trading prices, CTOR is priced at $0.76 on the NASDAQ, while RAD trades at $0.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTOR currently has a P/E ratio of -1.81, whereas RAD's P/E ratio is -0.05. In terms of profitability, CTOR's ROE is -1.03%, compared to RAD's ROE of +2.76%. Regarding short-term risk, CTOR is less volatile compared to RAD. This indicates lower risk in terms of short-term price fluctuations for CTOR.Check RAD's competition here
Damora Therapeutics, Inc. (NASDAQ: GLTO)
CTOR vs GLTO Comparison October 2026
Citius Oncology, Inc. (NASDAQ: CTOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTOR stands at 78.9M. In comparison, GLTO has a market cap of 34.5M. Regarding current trading prices, CTOR is priced at $0.76 on the NASDAQ, while GLTO trades at $21.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTOR currently has a P/E ratio of -1.81, whereas GLTO's P/E ratio is -1.78. In terms of profitability, CTOR's ROE is -1.03%, compared to GLTO's ROE of -0.83%. Regarding short-term risk, CTOR is more volatile compared to GLTO. This indicates higher risk in terms of short-term price fluctuations for CTOR.Check GLTO's competition here
Nasus Pharma Ltd. (AMEX: NSRX)
CTOR vs NSRX Comparison October 2026
Citius Oncology, Inc. (NASDAQ: CTOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTOR stands at 78.9M. In comparison, NSRX has a market cap of 28.6M. Regarding current trading prices, CTOR is priced at $0.76 on the NASDAQ, while NSRX trades at $3.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTOR currently has a P/E ratio of -1.81, whereas NSRX's P/E ratio is -4.61. In terms of profitability, CTOR's ROE is -1.03%, compared to NSRX's ROE of -1.59%. Regarding short-term risk, CTOR is more volatile compared to NSRX. This indicates higher risk in terms of short-term price fluctuations for CTOR.Check NSRX's competition here
SCYNEXIS, Inc. (NASDAQ: SCYX)
CTOR vs SCYX Comparison October 2026
Citius Oncology, Inc. (NASDAQ: CTOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTOR stands at 78.9M. In comparison, SCYX has a market cap of 25.3M. Regarding current trading prices, CTOR is priced at $0.76 on the NASDAQ, while SCYX trades at $4.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTOR currently has a P/E ratio of -1.81, whereas SCYX's P/E ratio is -1.18. In terms of profitability, CTOR's ROE is -1.03%, compared to SCYX's ROE of -0.21%. Regarding short-term risk, CTOR is more volatile compared to SCYX. This indicates higher risk in terms of short-term price fluctuations for CTOR.Check SCYX's competition here
Cosmos Health Inc. (NASDAQ: COSM)
CTOR vs COSM Comparison October 2026
Citius Oncology, Inc. (NASDAQ: CTOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTOR stands at 78.9M. In comparison, COSM has a market cap of 17.1M. Regarding current trading prices, CTOR is priced at $0.76 on the NASDAQ, while COSM trades at $0.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTOR currently has a P/E ratio of -1.81, whereas COSM's P/E ratio is -0.43. In terms of profitability, CTOR's ROE is -1.03%, compared to COSM's ROE of -1.19%. Regarding short-term risk, CTOR is less volatile compared to COSM. This indicates lower risk in terms of short-term price fluctuations for CTOR.Check COSM's competition here
Cerenome, Inc. (NASDAQ: CNSY)
CTOR vs CNSY Comparison October 2026
Citius Oncology, Inc. (NASDAQ: CTOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTOR stands at 78.9M. In comparison, CNSY has a market cap of 12.3M. Regarding current trading prices, CTOR is priced at $0.76 on the NASDAQ, while CNSY trades at $1.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTOR currently has a P/E ratio of -1.81, whereas CNSY's P/E ratio is -0.43. In terms of profitability, CTOR's ROE is -1.03%, compared to CNSY's ROE of -3.94%. Regarding short-term risk, CTOR is more volatile compared to CNSY. This indicates higher risk in terms of short-term price fluctuations for CTOR.Check CNSY's competition here
Biofrontera Inc. (NASDAQ: BFRI)
CTOR vs BFRI Comparison October 2026
Citius Oncology, Inc. (NASDAQ: CTOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTOR stands at 78.9M. In comparison, BFRI has a market cap of 11.8M. Regarding current trading prices, CTOR is priced at $0.76 on the NASDAQ, while BFRI trades at $0.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTOR currently has a P/E ratio of -1.81, whereas BFRI's P/E ratio is -1.68. In terms of profitability, CTOR's ROE is -1.03%, compared to BFRI's ROE of -1.28%. Regarding short-term risk, CTOR is more volatile compared to BFRI. This indicates higher risk in terms of short-term price fluctuations for CTOR.Check BFRI's competition here
China Jo-Jo Drugstores, Inc. (NASDAQ: CJJD)
CTOR vs CJJD Comparison October 2026
Citius Oncology, Inc. (NASDAQ: CTOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTOR stands at 78.9M. In comparison, CJJD has a market cap of 9.9M. Regarding current trading prices, CTOR is priced at $0.76 on the NASDAQ, while CJJD trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTOR currently has a P/E ratio of -1.81, whereas CJJD's P/E ratio is -0.46. In terms of profitability, CTOR's ROE is -1.03%, compared to CJJD's ROE of -0.25%. Regarding short-term risk, CTOR is more volatile compared to CJJD. This indicates higher risk in terms of short-term price fluctuations for CTOR.Check CJJD's competition here
SunLink Health Systems, Inc. (AMEX: SSY)
CTOR vs SSY Comparison October 2026
Citius Oncology, Inc. (NASDAQ: CTOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTOR stands at 78.9M. In comparison, SSY has a market cap of 7.9M. Regarding current trading prices, CTOR is priced at $0.76 on the NASDAQ, while SSY trades at $1.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTOR currently has a P/E ratio of -1.81, whereas SSY's P/E ratio is -2.86. In terms of profitability, CTOR's ROE is -1.03%, compared to SSY's ROE of -0.09%. Regarding short-term risk, CTOR is less volatile compared to SSY. This indicates lower risk in terms of short-term price fluctuations for CTOR.Check SSY's competition here
Scienture Holdings, Inc. (NASDAQ: SCNX)
CTOR vs SCNX Comparison October 2026
Citius Oncology, Inc. (NASDAQ: CTOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTOR stands at 78.9M. In comparison, SCNX has a market cap of 6.4M. Regarding current trading prices, CTOR is priced at $0.76 on the NASDAQ, while SCNX trades at $3.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTOR currently has a P/E ratio of -1.81, whereas SCNX's P/E ratio is -1.86. In terms of profitability, CTOR's ROE is -1.03%, compared to SCNX's ROE of -0.54%. Regarding short-term risk, CTOR is less volatile compared to SCNX. This indicates lower risk in terms of short-term price fluctuations for CTOR.Check SCNX's competition here
Bio Green Med Solution, Inc. (NASDAQ: BGMS)
CTOR vs BGMS Comparison October 2026
Citius Oncology, Inc. (NASDAQ: CTOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTOR stands at 78.9M. In comparison, BGMS has a market cap of 5.4M. Regarding current trading prices, CTOR is priced at $0.76 on the NASDAQ, while BGMS trades at $0.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTOR currently has a P/E ratio of -1.81, whereas BGMS's P/E ratio is -0.28. In terms of profitability, CTOR's ROE is -1.03%, compared to BGMS's ROE of -0.32%. Regarding short-term risk, CTOR is more volatile compared to BGMS. This indicates higher risk in terms of short-term price fluctuations for CTOR.Check BGMS's competition here
POMDOCTOR Ltd (NASDAQ: POM)
CTOR vs POM Comparison October 2026
Citius Oncology, Inc. (NASDAQ: CTOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTOR stands at 78.9M. In comparison, POM has a market cap of 4.2M. Regarding current trading prices, CTOR is priced at $0.76 on the NASDAQ, while POM trades at $0.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTOR currently has a P/E ratio of -1.81, whereas POM's P/E ratio is -0.11. In terms of profitability, CTOR's ROE is -1.03%, compared to POM's ROE of +0.16%. Regarding short-term risk, CTOR is more volatile compared to POM. This indicates higher risk in terms of short-term price fluctuations for CTOR.Check POM's competition here
Eocene Ltd. (NASDAQ: EOCN)
CTOR vs EOCN Comparison October 2026
Citius Oncology, Inc. (NASDAQ: CTOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTOR stands at 78.9M. In comparison, EOCN has a market cap of 3.4M. Regarding current trading prices, CTOR is priced at $0.76 on the NASDAQ, while EOCN trades at $3.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTOR currently has a P/E ratio of -1.81, whereas EOCN's P/E ratio is -0.23. In terms of profitability, CTOR's ROE is -1.03%, compared to EOCN's ROE of N/A. Regarding short-term risk, CTOR is more volatile compared to EOCN. This indicates higher risk in terms of short-term price fluctuations for CTOR.Check EOCN's competition here
Biofrontera Inc. (NASDAQ: BFRIW)
CTOR vs BFRIW Comparison October 2026
Citius Oncology, Inc. (NASDAQ: CTOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTOR stands at 78.9M. In comparison, BFRIW has a market cap of 3.2M. Regarding current trading prices, CTOR is priced at $0.76 on the NASDAQ, while BFRIW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTOR currently has a P/E ratio of -1.81, whereas BFRIW's P/E ratio is -0.01. In terms of profitability, CTOR's ROE is -1.03%, compared to BFRIW's ROE of -1.28%. Regarding short-term risk, CTOR is more volatile compared to BFRIW. This indicates higher risk in terms of short-term price fluctuations for CTOR.Check BFRIW's competition here
Paranovus Entertainment Technology Ltd. (NASDAQ: PAVS)
CTOR vs PAVS Comparison October 2026
Citius Oncology, Inc. (NASDAQ: CTOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTOR stands at 78.9M. In comparison, PAVS has a market cap of 3M. Regarding current trading prices, CTOR is priced at $0.76 on the NASDAQ, while PAVS trades at $3.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTOR currently has a P/E ratio of -1.81, whereas PAVS's P/E ratio is -0.04. In terms of profitability, CTOR's ROE is -1.03%, compared to PAVS's ROE of -0.46%. Regarding short-term risk, CTOR is more volatile compared to PAVS. This indicates higher risk in terms of short-term price fluctuations for CTOR.Check PAVS's competition here
MedAvail Holdings, Inc. (NASDAQ: MDVL)
CTOR vs MDVL Comparison October 2026
Citius Oncology, Inc. (NASDAQ: CTOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTOR stands at 78.9M. In comparison, MDVL has a market cap of 2.9M. Regarding current trading prices, CTOR is priced at $0.76 on the NASDAQ, while MDVL trades at $1.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTOR currently has a P/E ratio of -1.81, whereas MDVL's P/E ratio is -0.05. In terms of profitability, CTOR's ROE is -1.03%, compared to MDVL's ROE of -2.39%. Regarding short-term risk, CTOR is less volatile compared to MDVL. This indicates lower risk in terms of short-term price fluctuations for CTOR.Check MDVL's competition here
ETHZilla Corporation Warrant (NASDAQ: ATNFW)
CTOR vs ATNFW Comparison October 2026
Citius Oncology, Inc. (NASDAQ: CTOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTOR stands at 78.9M. In comparison, ATNFW has a market cap of 2.6M. Regarding current trading prices, CTOR is priced at $0.76 on the NASDAQ, while ATNFW trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTOR currently has a P/E ratio of -1.81, whereas ATNFW's P/E ratio is N/A. In terms of profitability, CTOR's ROE is -1.03%, compared to ATNFW's ROE of -2.15%. Regarding short-term risk, CTOR is less volatile compared to ATNFW. This indicates lower risk in terms of short-term price fluctuations for CTOR.Check ATNFW's competition here
Bio Green Med Solution, Inc. (NASDAQ: BGMSP)
CTOR vs BGMSP Comparison October 2026
Citius Oncology, Inc. (NASDAQ: CTOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTOR stands at 78.9M. In comparison, BGMSP has a market cap of 2.4M. Regarding current trading prices, CTOR is priced at $0.76 on the NASDAQ, while BGMSP trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTOR currently has a P/E ratio of -1.81, whereas BGMSP's P/E ratio is -0.84. In terms of profitability, CTOR's ROE is -1.03%, compared to BGMSP's ROE of -0.32%. Regarding short-term risk, CTOR is more volatile compared to BGMSP. This indicates higher risk in terms of short-term price fluctuations for CTOR.Check BGMSP's competition here
AstraZeneca PLC ADRhedged (AMEX: AZNH)
CTOR vs AZNH Comparison October 2026
Citius Oncology, Inc. (NASDAQ: CTOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTOR stands at 78.9M. In comparison, AZNH has a market cap of 1.6M. Regarding current trading prices, CTOR is priced at $0.76 on the NASDAQ, while AZNH trades at $53.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTOR currently has a P/E ratio of -1.81, whereas AZNH's P/E ratio is 38.35. In terms of profitability, CTOR's ROE is -1.03%, compared to AZNH's ROE of +0.00%. Regarding short-term risk, CTOR is more volatile compared to AZNH. This indicates higher risk in terms of short-term price fluctuations for CTOR.Check AZNH's competition here
Leafly Holdings, Inc. (NASDAQ: LFLYW)
CTOR vs LFLYW Comparison October 2026
Citius Oncology, Inc. (NASDAQ: CTOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTOR stands at 78.9M. In comparison, LFLYW has a market cap of 299.9K. Regarding current trading prices, CTOR is priced at $0.76 on the NASDAQ, while LFLYW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTOR currently has a P/E ratio of -1.81, whereas LFLYW's P/E ratio is -0.00. In terms of profitability, CTOR's ROE is -1.03%, compared to LFLYW's ROE of +0.42%. Regarding short-term risk, CTOR is more volatile compared to LFLYW. This indicates higher risk in terms of short-term price fluctuations for CTOR.Check LFLYW's competition here
ProPhase Labs, Inc. (NASDAQ: PRPH)
CTOR vs PRPH Comparison October 2026
Citius Oncology, Inc. (NASDAQ: CTOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTOR stands at 78.9M. In comparison, PRPH has a market cap of 126.1K. Regarding current trading prices, CTOR is priced at $0.76 on the NASDAQ, while PRPH trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTOR currently has a P/E ratio of -1.81, whereas PRPH's P/E ratio is N/A. In terms of profitability, CTOR's ROE is -1.03%, compared to PRPH's ROE of -13.59%. Regarding short-term risk, CTOR is less volatile compared to PRPH. This indicates lower risk in terms of short-term price fluctuations for CTOR.Check PRPH's competition here
Caraco Pharmaceutical Laboratories Ltd (AMEX: CPD)
CTOR vs CPD Comparison October 2026
Citius Oncology, Inc. (NASDAQ: CTOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTOR stands at 78.9M. In comparison, CPD has a market cap of 0. Regarding current trading prices, CTOR is priced at $0.76 on the NASDAQ, while CPD trades at $5.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTOR currently has a P/E ratio of -1.81, whereas CPD's P/E ratio is N/A. In terms of profitability, CTOR's ROE is -1.03%, compared to CPD's ROE of N/A. Regarding short-term risk, CTOR is more volatile compared to CPD. This indicates higher risk in terms of short-term price fluctuations for CTOR.Check CPD's competition here
Orexigen Therapeutics, Inc. (NASDAQ: OREX)
CTOR vs OREX Comparison October 2026
Citius Oncology, Inc. (NASDAQ: CTOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTOR stands at 78.9M. In comparison, OREX has a market cap of 0. Regarding current trading prices, CTOR is priced at $0.76 on the NASDAQ, while OREX trades at $0.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTOR currently has a P/E ratio of -1.81, whereas OREX's P/E ratio is -0.14. In terms of profitability, CTOR's ROE is -1.03%, compared to OREX's ROE of -0.54%. Regarding short-term risk, CTOR is less volatile compared to OREX. This indicates lower risk in terms of short-term price fluctuations for CTOR.Check OREX's competition here
POZEN Inc. (NASDAQ: POZN)
CTOR vs POZN Comparison October 2026
Citius Oncology, Inc. (NASDAQ: CTOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTOR stands at 78.9M. In comparison, POZN has a market cap of 0. Regarding current trading prices, CTOR is priced at $0.76 on the NASDAQ, while POZN trades at $5.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTOR currently has a P/E ratio of -1.81, whereas POZN's P/E ratio is N/A. In terms of profitability, CTOR's ROE is -1.03%, compared to POZN's ROE of +0.61%. Regarding short-term risk, CTOR is less volatile compared to POZN. This indicates lower risk in terms of short-term price fluctuations for CTOR.Check POZN's competition here
Impax Laboratories, Inc. (NASDAQ: IPXL)
CTOR vs IPXL Comparison October 2026
Citius Oncology, Inc. (NASDAQ: CTOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTOR stands at 78.9M. In comparison, IPXL has a market cap of 0. Regarding current trading prices, CTOR is priced at $0.76 on the NASDAQ, while IPXL trades at $18.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTOR currently has a P/E ratio of -1.81, whereas IPXL's P/E ratio is -10.11. In terms of profitability, CTOR's ROE is -1.03%, compared to IPXL's ROE of -1.16%. Regarding short-term risk, CTOR is more volatile compared to IPXL. This indicates higher risk in terms of short-term price fluctuations for CTOR.Check IPXL's competition here
Shire plc (NASDAQ: SHPG)
CTOR vs SHPG Comparison October 2026
Citius Oncology, Inc. (NASDAQ: CTOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTOR stands at 78.9M. In comparison, SHPG has a market cap of 0. Regarding current trading prices, CTOR is priced at $0.76 on the NASDAQ, while SHPG trades at $179.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTOR currently has a P/E ratio of -1.81, whereas SHPG's P/E ratio is 11.35. In terms of profitability, CTOR's ROE is -1.03%, compared to SHPG's ROE of +0.13%. Regarding short-term risk, CTOR is more volatile compared to SHPG. This indicates higher risk in terms of short-term price fluctuations for CTOR.Check SHPG's competition here
Express Scripts Holding Company (NASDAQ: ESRX)
CTOR vs ESRX Comparison October 2026
Citius Oncology, Inc. (NASDAQ: CTOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTOR stands at 78.9M. In comparison, ESRX has a market cap of 0. Regarding current trading prices, CTOR is priced at $0.76 on the NASDAQ, while ESRX trades at $92.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTOR currently has a P/E ratio of -1.81, whereas ESRX's P/E ratio is 10.69. In terms of profitability, CTOR's ROE is -1.03%, compared to ESRX's ROE of +0.26%. Regarding short-term risk, CTOR is more volatile compared to ESRX. This indicates higher risk in terms of short-term price fluctuations for CTOR.Check ESRX's competition here